Blocking cytokines with genes

Keyphrases

• Rheumatoid Arthritis 100%
• Gene Therapy 100%
• Rheumatoid Arthritis Treatment 100%
• Gene Products 100%
• Inflammatory Cytokines 50%
• Laboratory Research 50%
• Transforming Growth Factor-β 50%
• Phase I Trial 50%
• Gene Delivery 50%
• Therapeutic Efficacy 50%
• Messenger 50%
• Interleukin-1β 50%
• Systemic Administration 50%
• Human Patients 50%
• In Vivo Methods 50%
• Tumor Necrosis Factor-α 50%
• Interleukin-1 Receptor 50%
• Tumor Necrosis Factor Receptor 2 (TNFR2) 50%
• Joint Tissues 50%
• Therapeutic Gene 50%
• Interleukin-1 Receptor Antagonist (IL-1Ra) 50%
• Gene Delivery Vector 50%
• Therapeutic Implications 50%
• Rheumatoid Arthritis Patients 50%
• Biological Agents 50%
• Delivery Approaches 50%
• Synovial Cells 50%
• Viral IL-10 50%
• Local Gene Delivery 50%
• Tumor Necrosis Factor Receptor 1 (TNFR1) 50%

Medicine and Dentistry

• Rheumatoid Arthritis 100%
• Cytokine 100%
• Inflammatory Arthritis 100%
• Gene Targeting 60%
• Gene Therapy 40%
• Gene Product 40%
• Ex Vivo 20%
• Clinical Trial 20%
• Pathophysiology 20%
• Interleukin 1 20%
• Systemic Administration 20%
• Tumor Necrosis Factor 20%
• Synovial Cell 20%
• Interleukin 1 Receptor Blocking Agent 20%
• Interleukin 1 Receptor 20%
• Cancer Growth Factor 20%
• Tumor Necrosis Factor Receptor 20%
• Interleukin 10 20%
• Diseases 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Rheumatoid Arthritis 100%
• Cytokine 100%
• Inflammatory Arthritis 100%
• Gene Delivery 60%
• Clinical Trial 20%
• Tumor Necrosis Factor 20%
• Interleukin 1 20%
• Systemic Administration 20%
• Interleukin 1 Receptor Blocking Agent 20%
• Interleukin 1 Receptor 20%
• Cancer Growth Factor 20%
• Pathophysiology 20%
• Tumor Necrosis Factor Receptor 20%
• Interleukin 10 20%
• Diseases 20%